"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026. Posters highlighted sex-based differences in aggressive ...

“This multicenter real-world study suggests that first-line tislelizumab combined with platinum-etoposide chemotherapy provides encouraging efficacy with an acceptable safety profile in patients with ...

T-cell lymphomas represent a heterogeneous and often aggressive group of hematologic malignancies for which the optimal consolidation strategy, autologous or allogeneic hematopoietic stem cell ...

The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.

Ottensmeier C, Delord JP, Lalanne A, et al. A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized phase I trial. Nat ...

The second clinical scenario considers a 72-year-old patient with multiple myeloma who is triple-class exposed and has experienced disease progression after a BCMA-directed T-cell-engaging therapy.

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.

Forsyth P, Law V, Grogan P, et al. Intrathecal dendritic cell therapy in a first-in-human trial for breast cancer ...

The journal ONCOLOGY ® provides oncology professionals with practical and timely clinical information necessary to deliver the highest level of patient care. Expert authors and peer review ensure the ...

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of ...

A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...